Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-17T01:35:20.847Z Has data issue: false hasContentIssue false

Diphenylhydantoin and Pulmonary Function

Published online by Cambridge University Press:  18 September 2015

Ronald J. Smith
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
Godfrey C. W. Man
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
S. F. Paul Man
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
Donald R. McLean*
Affiliation:
Department of Medicine, Divisions of Neurology and Pulmonary Medicine, University of Alberta, Edmonton
*
Division of Neurology, 9-101 Clinical Sciences, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Thirty-nine epileptic patients underwent pulmonary function testing. Twenty-one of these patients, ranging in age from 16 to 44 years, had taken diphenylhydantoin (DPH) for 2 to 17 years. Eighteen patients, who had taken other anticonvulsants for similar time periods served as controls. Five patients in the DPH group had lung volume abnormalities, four had abnormal airway function, and five had abnormalities of alveolar gas mixing. One patient in the control group had lung volume abnormalities, two had abnormal airway function, and five had abnormalities of alveolar gas mixing. Statistical analysis revealed no significant differences between the groups, or between either group and predicted values.

Information

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1979